This women's healthcare company raised $7.5 million in a public offering and says it's targeting $25 to $30 million net revenue by end of 2023

Agile says growing demand for twirla (levonorgestrel and ethinyl estradiol ) transdermal system is helping it stay on track to hit $25-$30 million net revenue princeton, nj / accesswire / july 3, 2023 / agile therapeutics (nasdaq:agrx) announced the closing of its public offering in may. the women's healthcare company raised $7.5 million in gross proceeds after selling over 1.8 million shares of common stock at $3.95 per share.
AGRX Ratings Summary
AGRX Quant Ranking